和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02142 和铂医药-B

未开盘 03-25 16:08:32

12.180

+0.480

+4.10%

最高12.220	最低11.760	成交量304.10万
今开11.780	昨收11.700	日振幅3.93%
总市值105.97亿	流通市值105.97亿	总股本8.70亿
成交额3,670万	换手率0.35%	流通股本8.70亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02142","market":"HK","secType":"STK","nameCN":"和铂医药-B","latestPrice":12.18,"timestamp":1774426112004,"preClose":11.7,"halted":0,"volume":3041000,"delay":0,"changeRate":0.04102564102564107,"floatShares":869999999,"shares":869999999,"eps":0.003616,"marketStatus":"未开盘","change":0.48,"latestTime":"03-25 16:08:32","open":11.78,"high":12.22,"low":11.76,"amount":36700040,"amplitude":0.039316,"askPrice":12.18,"askSize":2000,"bidPrice":12.16,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":0.661,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774488600000},"marketStatusCode":0,"adr":0,"listingDate":1607529600000,"exchange":"SEHK","adjPreClose":11.7,"openAndCloseTimeList":[[1774402200000,1774411200000],[1774414800000,1774425600000]],"volumeRatio":1.1044103998653434,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02142","defaultTab":"news","newsList":[{"id":"2621059310","title":"港股异动 | TSLP抗体疗法I期临床研究结果发表 科伦博泰生物-B(06990)涨超7% 和铂医药-B(02142)涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621059310","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621059310?lang=zh_cn&edition=full","pubTime":"2026-03-24 15:02","pubTimestamp":1774335720,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物-B、和铂医药-B午后涨幅扩大。截至发稿，科伦博泰生物涨7.34%，报426.8港元；和铂医药涨4.65%，报11.7港元。消息面上，3月23日，和铂医药宣布，HBM9378首次人体1期临床试验结果已在线发表于同行评议期刊Drug Design, Development and Therapy。公开资料显示，HBM9378由和铂医药与科伦博泰联合开发，双方共同享有其全球权益。2025年1月，和铂医药及科伦博泰与Windward Bio签订战略合作，授予后者在全球范围内对该抗体进行研究、开发、生产和商业化的独家权益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417947.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990","BK1161","BK4588","BK1583","02142","BK1574","LU0196878994.USD","VXUS","BK4585"],"gpt_icon":0},{"id":"1174660573","title":"和铂医药任命谢博士为免疫学首席科学官兼全球外部创新负责人","url":"https://stock-news.laohu8.com/highlight/detail?id=1174660573","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174660573?lang=zh_cn&edition=full","pubTime":"2026-03-19 14:43","pubTimestamp":1773902595,"startTime":"0","endTime":"0","summary":"和铂医药-B（股票代码：02142）宣布一项重要人事任命，谢博士（Dr. Jenny Xie）正式加入公司，担任免疫学首席科学官兼全球外部创新负责人。这一任命将进一步加强公司在免疫学领域的科研实力与全球创新合作网络。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02142","BK1161","BK1583"],"gpt_icon":0},{"id":"2620316962","title":"和铂医药-B(02142.HK)拟3月30日举行董事会会议以审批年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2620316962","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620316962?lang=zh_cn&edition=full","pubTime":"2026-03-18 17:47","pubTimestamp":1773827222,"startTime":"0","endTime":"0","summary":"格隆汇3月18日丨和铂医药-B(02142.HK)公告，谨定于2026年3月30日(星期一)举行董事会会议，以考虑及通过集团截至2025年12月31日止年度的全年业绩，以及处理其他事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260318/32078568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","BK1583","BK1161","02142"],"gpt_icon":0},{"id":"2619109634","title":"5个月股价最大跌幅超40%，和铂医药-B(02142)BD利好成“出货”信号？","url":"https://stock-news.laohu8.com/highlight/detail?id=2619109634","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619109634?lang=zh_cn&edition=full","pubTime":"2026-03-15 20:27","pubTimestamp":1773577642,"startTime":"0","endTime":"0","summary":"自去年9月初股价触及最高17.98港元以来，和铂医药-B股价持续波动下跌，并在今年2月初，一度跌至最低10.61港元，区间振幅超过40%。截至3月13日，和铂医药股价为12港元，对应PE估值为18.18倍，低于行业平均的18.29倍。BD利好成“出货”信号?这也是和铂达成12亿美元BD的核心要素。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414030.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1574","BK1161","02142"],"gpt_icon":0},{"id":"2618490009","title":"和铂医药-B03月11日主力净流入100万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2618490009","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618490009?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:15","pubTimestamp":1773216926,"startTime":"0","endTime":"0","summary":"03月11日, 和铂医药-B股价涨0.16%，报收12.26元，成交金额1851.3万元，换手率0.17%，振幅4.17%，量比0.51。和铂医药-B今日主力资金净流入100万元，上一交易日主力净流出150.6万元。该股近5个交易日上涨6.46%，主力资金累计净流入119.6万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入518.8万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311161638a460a805&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311161638a460a805&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02142","BK1574","BK1583","BK1161"],"gpt_icon":0},{"id":"2618382059","title":"每日卖空追踪 | 和铂医药-B 03月10日卖空量成交5万股，卖空比例为1.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618382059","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618382059?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:30","pubTimestamp":1773131428,"startTime":"0","endTime":"0","summary":"和铂医药-B北京时间03月10日，涨6.34%，卖空量成交5万股，较上一交易日减少85.29%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310163328a45df78d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310163328a45df78d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02142","BK1583","BK1574"],"gpt_icon":0},{"id":"2618938741","title":"和铂医药-B盘中异动 股价大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618938741","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618938741?lang=zh_cn&edition=full","pubTime":"2026-03-10 11:42","pubTimestamp":1773114161,"startTime":"0","endTime":"0","summary":"2026年03月10日临近午盘11时42分，和铂医药-B股票出现异动，股价快速拉升5.04%。截至发稿，该股报12.090港元/股，成交量103.6万股，换手率0.12%，振幅3.82%。机构评级方面，在所有3家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。和铂医药-B股票所在的生物技术行业中，整体涨幅为4.31%。其相关个股中，百奥赛图-B、加科思-B、康方生物涨幅较大，振幅较大的相关个股有云康集团、百奥赛图-B、轩竹生物-B，振幅分别为20.88%、18.26%、15.86%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310114241a6b41e88&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310114241a6b41e88&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02142","BK1161","BK1583"],"gpt_icon":0},{"id":"1110338327","title":"和铂医药-B获NMPA批准HBM7575（SKB575）针对特应性皮炎的新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1110338327","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110338327?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:36","pubTimestamp":1773045381,"startTime":"0","endTime":"0","summary":"中国国家药品监督管理局（NMPA）已正式批准和铂医药-B（HBM HOLDINGS-B）提交的HBM7575（亦称SKB575）新药临床试验申请。该药物将用于治疗特应性皮炎，标志着公司在免疫性疾病治疗领域的研发取得重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02142","BK1574","BK1583"],"gpt_icon":0},{"id":"2618469286","title":"和铂医药-B(02142)：HBM7575用于治疗特应性皮炎的新药临床试验申请获NMPA 批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2618469286","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618469286?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:32","pubTimestamp":1773045134,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B(02142)公布，用于治疗特应性皮炎的靶向胸腺基质淋巴细胞生成素(TSLP)及一个未公开靶点的长效双特异性抗体HBM7575(亦称 SKB575)的新药临床试验(IND)申请已获中国国家药品监督管理局(NMPA)批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411603.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B(02142)：HBM7575用于治疗特应性皮炎的新药临床试验申请获NMPA 批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","BK1583","02142"],"gpt_icon":0},{"id":"2618649166","title":"科伦博泰/和铂医药超长效 TSLP 双抗首次获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2618649166","media":"药械Talks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618649166?lang=zh_cn&edition=full","pubTime":"2026-03-09 13:17","pubTimestamp":1773033479,"startTime":"0","endTime":"0","summary":"3 月 9 日，CDE 官网显示，科伦博泰与和铂医药共同申报的 SKB575注射液获批临床，用于治疗特应性皮炎。此次获批标志着双方在自身免疫领域的合作管线再获突破性进展。此外，科伦博泰与和铂医药还合作开发了一款TSLP 单抗 SKB378，该产品目前正在开展用于哮喘的 II 期临床。2025 年 1 月，SKB378 以 NewCo 形式已被授权给 Windward Bio，其中首付款和里程碑付款为 9.7 亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309144920a45a8995&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309144920a45a8995&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1161","BK1574","02142"],"gpt_icon":0},{"id":"2618649125","title":"和铂医药-B盘中异动 股价大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618649125","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618649125?lang=zh_cn&edition=full","pubTime":"2026-03-09 09:44","pubTimestamp":1773020640,"startTime":"0","endTime":"0","summary":"2026年03月09日早盘09时44分，和铂医药-B股票出现异动，股价急速跳水5.06%。截至发稿，该股报11.450港元/股，成交量45.9万股，换手率0.05%，振幅2.82%。和铂医药-B股票所在的生物技术行业中，整体跌幅为3.19%。其相关个股中，科济药业-B、维立志博-B、永泰生物-B涨幅较大，振幅较大的相关个股有科济药业-B、派格生物医药-B、维立志博-B，振幅分别为31.19%、15.64%、12.63%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309094400a6b09003&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309094400a6b09003&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1583","BK1161","02142"],"gpt_icon":0},{"id":"1112026828","title":"和铂医药-B（02142）2月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1112026828","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112026828?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:51","pubTimestamp":1772700662,"startTime":"0","endTime":"0","summary":"和铂医药控股有限公司于2026年3月5日公布截至2026年2月28日的股份变动月报表。公告显示，公司本月股本总体保持稳定，未有新的发行、转让或注销活动。公司截至2月末的法定股本数量为20,000,000,000股，面值每股USD 0.000025，注册股本合计USD 500,000。报告期内已发行股份为869,591,522股，库存股份为25,937,000股，与上月保持一致。综上，截至2月28日，公司已发行股份及注册股本均无实质变动，整体股本结构保持稳定。公告由执行董事王劲松签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"gpt_icon":0},{"id":"2617150960","title":"每日卖空追踪 | 和铂医药-B 03月05日卖空量成交11.6万股，卖空比例为5.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617150960","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617150960?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:30","pubTimestamp":1772699428,"startTime":"0","endTime":"0","summary":"和铂医药-B北京时间03月05日，涨1.92%，卖空量成交11.6万股，较上一交易日减少83.57%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305163347a44ef7d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305163347a44ef7d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1574","BK1161","02142"],"gpt_icon":0},{"id":"2616553371","title":"每日卖空追踪 | 和铂医药-B 03月03日卖空量成交10.8万股，卖空比例为4.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616553371","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616553371?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:30","pubTimestamp":1772526629,"startTime":"0","endTime":"0","summary":"和铂医药-B北京时间03月03日，跌3.14%，卖空量成交10.8万股，较上一交易日减少72.16%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303163341a445cb7d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303163341a445cb7d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1161","BK1574","02142"],"gpt_icon":0},{"id":"2616568371","title":"“爆单”出海 中国创新药开年出海总额超530亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616568371","media":"中国商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616568371?lang=zh_cn&edition=full","pubTime":"2026-03-03 15:41","pubTimestamp":1772523676,"startTime":"0","endTime":"0","summary":"2026年开年，中国药企出海节奏密集，截至2月25日，年内中国创新药已发生44起对外授权交易事件，首付款约为31.23亿美元，总金额达532.76亿美元。一季度未过，创新药出海交易总额已超过2025年全年总额的1/3。根据协议，荣昌生物将获得6.5亿美元首付款，并有资格获得最高达49.5亿美元的里程碑付款，交易总额高达56亿美元。到了2月25日，这一数字已攀升至532.76亿美元。小核酸药物正成为出海的新引擎。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303155542a69c7e68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303155542a69c7e68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","BK1583","BK1161","02142","09995","BK1574"],"gpt_icon":0},{"id":"2614009604","title":"中泰证券：维持和铂医药-B(02142)“买入”评级 仅重链抗体HBM4003出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2614009604","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614009604?lang=zh_cn&edition=full","pubTime":"2026-02-27 09:29","pubTimestamp":1772155785,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中泰证券发布研报称，维持和铂医药-B“买入”评级。中泰证券主要观点如下：事件2026年2月23日，和铂医药宣布与Solstice Oncology达成授权协议及股权合作，授予对方一款临床阶段候选产品HBM4003在大中华区以外地区的独家开发及商业化权益。HBM4003在I期单药研究试验中显示了其良好的安全性和强大的疗效潜在适应症包括黑色素瘤、非小细胞肺癌、肝细胞癌、神经内分泌瘤等多种晚期实体肿瘤。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407956.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02142","600918"],"gpt_icon":0},{"id":"2613732656","title":"每日卖空追踪 | 和铂医药-B 02月23日卖空量成交27.8万股，卖空比例为4.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613732656","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613732656?lang=zh_cn&edition=full","pubTime":"2026-02-23 16:30","pubTimestamp":1771835427,"startTime":"0","endTime":"0","summary":"和铂医药-B北京时间02月23日，涨4.41%，卖空量成交27.8万股，较上一交易日增加8.59%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223163326a4be7d3d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223163326a4be7d3d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","02142","BK1574","BK1161"],"gpt_icon":0},{"id":"2613927026","title":"港股异动 | 和铂医药-B(02142)早盘涨超8% 新一代CTLA-4抗体出海 总额或超12亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613927026","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613927026?lang=zh_cn&edition=full","pubTime":"2026-02-23 09:46","pubTimestamp":1771811192,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B(02142)早盘涨超8%，截至发稿，涨7.92%，报13.21港元，成交额2179.47万港元。消息面上，2月23日，和铂医药宣布将新一代CTLA-4抗体HBM4003大中华区外全球权益授权Solstice Oncology，后者支付逾1.05亿美元前期对价，包括5000万美元首付款，500万美元近期付款以及价值逾5000万美元的公司股权。此外，和铂医药还将获得最高11亿美元的里程碑付款，以及分级销售分成。公开资料显示，Solstice Oncology为一家多个头部风险投资机构联合创立的临床阶段生物技术公司，此次合作为NewCo模式。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406231.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02142","BK4588","BK1583","BK1161","BK4585","VT","VXUS","BK1574"],"gpt_icon":0},{"id":"2613325057","title":"和铂医药-B盘中异动 早盘股价大涨5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613325057","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613325057?lang=zh_cn&edition=full","pubTime":"2026-02-23 09:31","pubTimestamp":1771810275,"startTime":"0","endTime":"0","summary":"2026年02月23日早盘09时31分，和铂医药-B股票出现异动，股价快速拉升5.39%。截至发稿，该股报12.900港元/股，成交量26万股，换手率0.03%，振幅2.94%。和铂医药-B股票所在的生物技术行业中，整体跌幅为1.06%。其相关个股中，和铂医药-B、云康集团、药明生物涨幅较大，振幅较大的相关个股有康宁杰瑞制药-B、云康集团、复宏汉霖，振幅分别为4.67%、4.29%、2.98%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602230931159541a2bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602230931159541a2bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1583","BK1161","02142"],"gpt_icon":0},{"id":"2613927206","title":"和铂医药-B(02142)与Solstice Oncology就HBM4003订立独家授权协议及股权合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2613927206","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613927206?lang=zh_cn&edition=full","pubTime":"2026-02-23 08:10","pubTimestamp":1771805456,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B 发布公告，公司已与Solstice Oncology订立独家授权协议及股权合作协议，据此，公司同意向Solstice Oncology授予独家授权，以在大中华区以外地区开发及商业化其临床阶段组合资产HBM4003。根据该等协议的条款，公司有资格获得价值超过1.05亿美元的前期对价，包括：5000万美元的首付款，500万美元的近期付款，及向公司发行及配发于Solstice Oncology的超过5000万美元的股权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406208.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B(02142)与Solstice Oncology就HBM4003订立独家授权协议及股权合作协议","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02142","BK1574","BK1583","BK1161"],"gpt_icon":1}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0217},{"period":"1month","weight":-0.0469},{"period":"3month","weight":-0.0645},{"period":"6month","weight":-0.1306},{"period":"1year","weight":0.5359},{"period":"ytd","weight":0.0016}],"compareEarnings":[{"period":"1week","weight":-0.0265},{"period":"1month","weight":-0.0645},{"period":"3month","weight":-0.0187},{"period":"6month","weight":-0.0303},{"period":"1year","weight":0.0853},{"period":"ytd","weight":-0.0115}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和铂医药控股有限公司是一家主要从事肿瘤免疫学及免疫性疾病领域的创新疗法开发业务的投资控股公司。该公司的产品主要包括巴托利单抗（HBM9161）、HBM9378、HBM7020、TCE Program、普鲁苏拜单抗（HBM4003）以及HBM7022等。该公司产品主要用于治疗全身型重症肌无力（gMG）、慢性阻塞性肺病（COPD）、哮喘、自身免疫疾病、黑色素瘤、结直肠癌以及实体瘤等。该公司通过专有抗体技术平台“Harbour Mice”、“HBICE”、“HBICA”及单克隆B细胞筛选平台提供下一代抗体以及生物解决方案。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.083377},{"month":2,"riseRate":0.333333,"avgChangeRate":0.000026},{"month":3,"riseRate":0.5,"avgChangeRate":0.038939},{"month":4,"riseRate":0.4,"avgChangeRate":0.013317},{"month":5,"riseRate":0.6,"avgChangeRate":0.040454},{"month":6,"riseRate":0.2,"avgChangeRate":-0.066065},{"month":7,"riseRate":0.4,"avgChangeRate":0.030357},{"month":8,"riseRate":0.2,"avgChangeRate":0.005624},{"month":9,"riseRate":0.4,"avgChangeRate":-0.065735},{"month":10,"riseRate":0,"avgChangeRate":-0.180686},{"month":11,"riseRate":0.8,"avgChangeRate":0.25789},{"month":12,"riseRate":0.6,"avgChangeRate":0.266929}],"exchange":"SEHK","name":"和铂医药-B","nameEN":"HBM HOLDINGS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和铂医药-B,02142,和铂医药-B股票,和铂医药-B股票老虎,和铂医药-B股票老虎国际,和铂医药-B行情,和铂医药-B股票行情,和铂医药-B股价,和铂医药-B股市,和铂医药-B股票价格,和铂医药-B股票交易,和铂医药-B股票购买,和铂医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}